ABSTRACT
Malignant peripheral nerve sheath tumors (MPNST) are the deadliest cancer that arises in individuals diagnosed with neurofibromatosis and account for nearly 5% of the 15,000 soft tissue sarcomas diagnosed in the United States each year. Comprised of neoplastic Schwann cells, primary risk factors for developing MPNST include existing plexiform neurofibromas (PN), prior radiotherapy treatment, and expansive germline mutations involving the entire NF1 gene and surrounding genes. PN develop in nearly 30-50% of patients with NF1 and most often grow rapidly in the first decade of life. One of the most important aspects of clinical care for NF1 patients is monitoring PN for signs of malignant transformation to MPNST that occurs in 10-15% of patients.
We perform aneuploidy analysis on ctDNA from 883 ostensibly healthy individuals and 28 patients with neurofibromas, including 7 patients with benign neurofibroma, 9 patients with PN and 12 patients with MPNST. Overall sensitivity for detecting MPNST using genome wide aneuploidy scoring was 33%, and analysis of sub-chromosomal copy number alterations (CNAs) improved sensitivity to 50% while retaining a high specificity of 97%. In addition, we performed mutation analysis on plasma cfDNA for a subset of patients and identified mutations in NF1, NF2, RB1, TP53BP2, and GOLGA2. Given the high throughput and relatively low sequencing coverage required by our assay, liquid biopsy represents a promising technology to identify incipient MPNST.
Competing Interest Statement
CB is a consultant for Depuy-Synthes and Bionaut Pharmaceuticals. CD is a consultant to Exact Sciences and is compensated with income and equity. The company named above as well as other companies have licensed previously described technologies related to the work described in this paper from Johns Hopkins University. CD is an inventor on some of these technologies. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors as well as to Johns Hopkins University. The terms of all of these arrangements are being managed by Johns Hopkins University in accordance with its conflict of interest policies.
Funding Statement
This work was supported by grants from the NIH: 1R21CA208723-01, R37 CA230400, U01 CA230691. In addition a grant from the DOD W81XWH-16-0078, grant 2014107 from the Doris Duke Charitable Foundation and a Burroughs Wellcome Career Award for Medical Scientists all supported this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All individuals participating in the study provided written informed consent after approval by the institutional review board at The Johns Hopkins IRB00075499.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
FUNDING This work was supported by grants from the NIH: 1R21CA208723-01, R37 CA230400, U01 CA230691. In addition a grant from the DOD W81XWH-16-0078, grant 2014107 from the Doris Duke Charitable Foundation and a Burroughs Wellcome Career Award for Medical Scientists all supported this work.
CONFLICT OF INTEREST CB is a consultant for Depuy-Synthes and Bionaut Pharmaceuticals. CD is a consultant to Exact Sciences and is compensated with income and equity. The company named above as well as other companies have licensed previously described technologies related to the work described in this paper from Johns Hopkins University. CD is an inventor on some of these technologies. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors as well as to Johns Hopkins University. The terms of all of these arrangements are being managed by Johns Hopkins University in accordance with its conflict of interest policies.
Data Availability
All data are available upon request.
